Search Results for "Antidepressants"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Antidepressants. Results 1 to 10 of 45 total matches.
In Brief: Off-Label Amitriptyline for Insomnia
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
said
there is little evidence that antidepressants such as
trazodone, mirtazapine, or amitriptyline ...
In our article on Drugs for Chronic Insomnia, we said
there is little evidence that antidepressants such as
trazodone, mirtazapine, or amitriptyline are effective
in treating insomnia not associated with depression.
We received a comment from a reader who has
prescribed the tricyclic antidepressant amitriptyline
for insomnia, particularly for patients with headache
disorders, and finds that most patients are satisfied
with the treatment.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):48 doi:10.58347/tml.2023.1672d | Show Introduction Hide Introduction
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
not respond to monotherapy, combining two antidepressants, such as bupropion and an SSRI, or adding a second ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Gepirone (Exxua) for Depression
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
or with congenital long QT syndrome.
All antidepressants can induce mania, most often
in patients with undetected ...
The FDA has approved an oral extended-release
formulation of gepirone (Exxua – Fabre-Kramer), a
selective 5-HT1A receptor agonist, for treatment of
major depressive disorder (MDD) in adults. Gepirone
was originally developed decades ago for treatment
of anxiety and depression, but it was not approved by
the FDA for such use. Gepirone is structurally related
to buspirone, which is FDA-approved for treatment
of anxiety.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):97-9 doi:10.58347/tml.2024.1705a | Show Introduction Hide Introduction
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
successful treatment of a first
major depressive episode, antidepressant treatment
should be continued ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Cariprazine (Vraylar) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
TREATMENT OF DEPRESSION —
When antidepressant monotherapy is inadequate,
augmentation with a second ...
The FDA has approved the second-generation
antipsychotic drug cariprazine (Vraylar — Abbvie) for
adjunctive treatment of major depressive disorder
(MDD) in adults. Cariprazine was previously approved
for treatment of schizophrenia and bipolar depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6 doi:10.58347/tml.2023.1677c | Show Introduction Hide Introduction
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
postpartum.
Women already taking another oral antidepressant
(15-19%) were allowed to continue it. In both ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction
A New Indication for Esketamine Nasal Spray (Spravato)
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020 (Issue 1607)
for this indication. Most clinical trials of
antidepressants have excluded patients with acute
suicidal ideation ...
Esketamine (Spravato – Janssen), an intranasal
N-methyl-D-aspartate (NMDA) receptor antagonist
that was previously approved by the FDA for treatmentresistant
depression,1 has now been approved for
treatment of depressive symptoms in adults with
major depressive disorder (MDD) and acute suicidal
ideation or behavior. Esketamine is the S-enantiomer
of the anesthetic ketamine (Ketalar, and generics).
It is the first drug to be approved for this indication.
Most clinical trials of antidepressants have excluded
patients with acute suicidal ideation.
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
antidepressant
doxepin in low doses (Silenor, and generics), or
suvorexant may be more effective, but they can ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
not be used1
Tricyclic Antidepressants (TCAs)
(such as amitriptyline, desipramine
[Norpramin, and generics ...
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
or other antispasmodics can be used for
abdominal pain or postprandial symptoms.
Antidepressants (TCAs or SSRIs) can ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant bowel
symptom as IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed type (IBS-M), or unclassified
(IBS-U). Alterations in the microbiome, stress
responses, sensory and motor function of the gut,
and host genetic factors may be contributing factors.
Since the exact cause of IBS is unknown, the goal of
treatment is symptom control.